Activaero Cooperates with Bayer HealthCare in the Development of Inhaled Treatments
Bayer licenses rights to Activaero's pulmonary delivery platform
Dr. Gerhard Scheuch, Founder and CEO of Activaero commented: "This licensing deal represents a major milestone for Activaero and together with our scientific team, we look forward to supporting Bayer HealthCare throughout the upcoming development. We believe that pulmonary administration of drugs has a huge potential for the treatment of lung diseases and diseases which start in the lung. With this in mind, it will be exciting to develop innovative therapies with Bayer HealthCare, a world-wide leader in the pharmaceutical business for decades."
Activaero has been supported in the strategy, negotiation and process of this licensing transaction by Tytonis B.V.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.